Articles

Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.

Coya Therapeutics Secures Rights to Exosome Engineering Technology from Carnegie Mellon University

Bio-Rad’s CFX Opus Deepwell Real-Time PCR Detection System is designed to support researchers in developing nucleic acid detection assays.

Bio-Rad Launches CFX Opus Deepwell Real-Time PCR Detection System

Bio-Rad’s EconoFit Chromatography Column Packs support resin screening experiments in the development of protein purification workflows.

Bio-Rad Launches New Chromatography Column Packs

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Some states look to block access to approved drugs. 

FDA Drug Regulation Challenged by Anti-Abortion Campaign

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies

NRG Therapeutics and Domainex aim to develop novel small-molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.

NRG Therapeutics and Domainex Partner on Parkinson’s Disease Drug Development Project

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

LG Chem Renews License with Avacta for IND Studies

Tanya Landon is a partner, Global Arbitration, Trade and Advocacy at Sidley Austin—an international law firm.

Dorothee Schramm is a partner, Global Arbitration, Trade and Advocacy at Sidley Austin—an international law firm.

As a result of the disruptions caused by the COVID-19 pandemic, global arbitration has adapted to a ‘new normal’.

Trends in International Arbitration: The Fallout from COVID-19

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Process Development Struggles with Molecular Diversity

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Dame Deborah James’ legacy and the millions raised through her campaigning will undoubtedly be a big boost to clinical research, ultimately providing new and promising treatments for bowel cancer patients. 

News